CJC

The synergy only works if you time both peptides right. Covers 100-300mcg each, pre-mixed blends, and 12-week cycling.

After 30, your body starts shutting down what built you. Growth hormone output drops approximately 14% per decade (Iranmanesh et al., 1991), and with it goes the deep sleep, fast recovery, and lean body composition you took for granted in your twenties. The decline is gradual enough that most people don’t notice it — until they do.

CJC-1295 and Ipamorelin have become the most widely used growth hormone peptide stack for a reason: they work through complementary mechanisms, produce synergistic GH release, and do so with a cleaner side effect profile than nearly any other combination in the GH secretagogue space. This isn’t exogenous growth hormone. This is your own biology, unlocked.

This guide covers the science behind why this stack works, what the clinical evidence actually shows, practical dosing protocols, reconstitution details, what to expect and when, and how it compares to alternatives. For the foundational science on GHRH vs GHRP mechanisms, see our GHRH vs GHRP mechanistic breakdown.

Combined Blend Option: Many vendors sell pre-mixed 5mg CJC-1295 + 5mg Ipamorelin blends. Dose: 250 mcg of each (20 units on insulin syringe with 2mL reconstitution) once or twice daily.

This allows you to gauge individual response and side effect sensitivity before increasing.

This blend combines CJC-1295 (no DAC), a modified growth hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue (GHS)[1][2]. CJC-1295 (no DAC) produces sustained, dose-dependent GH and IGF-1 increases[1], while Ipamorelin selectively stimulates GH release without raising ACTH or cortisol[3]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.